7th Annual Pharma Pricing, Reimbursement & Market Access 2023

7th Annual Pharma Pricing, Reimbursement & Market Access 2023

24th & 25th May 2023, The Conference Center at Waltham Woods, Waltham, (Boston, USA)

This conference will provide an overview of global pharma pricing, market access systems and cost management techniques, as well as in-depth discussion of some of the most current trends and changes. This conference will bring together top pharmaceutical, biotechnology and regulatory representatives under one roof that will address the key issues of the industry. It will be studied with the help of case studies and industry experiences. Following a raft of health policy reforms impacting pharmaceutical pricing in almost every major country in the EU, it gives me great pleasure in welcoming all of you to the Virtue Insight’s 7th Annual Pharma Pricing, Reimbursement & Market Access 2023.

Please contact Kavitha at E-mail - kavitha@virtueinsight.co.in   or call +44 20 3509 3779

DELEGATE REGISTRATION:

EARLY BIRD (VALID TILL 27th April)

1 Delegate @ $1400

Group Discount @ $2800 (3 Delegates for the price of 2)

STANDARD PRICE

1 Delegate @ $1600

Group Discount @ $3200 (3 Delegates for the price of 2)

SPONSORS:

Red Nucleus

We have sponsorship opportunities available for the event, which gives you an opportunity to speak/exhibit, and create brand awareness.  Here you can have a dedicated networking time, meet the leading international vendors and expand your knowledge of the latest business models. Please email to kavitha@virtueinsight.co.in   for more details.

KEY SPEAKERS:

• DAVID BOWER, Senior Director - U.S. Value & Access – Dermatology, Sanofi Genzyme
• MALLORY O’CONNOR, Executive Director, Public Policy, Mallinckrodt Pharmaceuticals
• GREG APOSTOL, Vice President & Head of Market Access, Alkermes
• BOXIONG TANG, Executive Director, Health Economics and, Outcomes Research (HEOR), BeiGene
• CHARLES BROWN, Director, Global Pricing and Contracting, Global Value & Access, Novartis Gene Therapies
• RICHARD LINER, Senior Assistant General Counsel, Bayer
• SUVINA AMIN, Director, Worldwide HEOR, Hematology, Bristol-Myers Squibb
• RITU NADKARNI, Commercial Director, SouthEast US, Biogen
• LAURENE REDDING, Global Head Strategic Pricing, BeiGene
• MARGARET REHAYEM, Vice President, National Alliance of Healthcare Purchaser Coalitions
• GARY ELLEXSON, VP Corporate Accounts, Supernus Pharmaceuticals
• PETER BARSCHORFF, Vice President, Deallus
• ROBERT ROUSE, Head of Market Access, CSL Behring
• HEATHER LEIGH FLANNERY, Founder & Chief Executive Officer, Equideum Health
• ROBERT POPOVIAN, VP Health Economics & Policy, Equideum Health
• SEAN MANION, CSO, Equideum Health
• JASON M. NOTO, Senior VP, US Market Access, AVEO Oncology
• SARAH EMOND, Executive VP & COO, Institute for Clinical and Economic Review (ICER)
• SCOTT HOWELL, Former US Pharma Chief Strategy Officer, Novartis
• USMAN IQBAL, Chief Medical Officer, Julz Pharma
• ANGELINA IRIZARI-POLICARPIO, Head of the U.S. HEOR & RWE Field Communications Team, Eisai
• YAOZHU (JULIETTE) CHEN, Global Evidence and Outcomes Lead, Takeda
• IGOR RUDYCHEV, VP, Enterprise Analytics, Horizon Therapeutics
• ALEEN HOSDAGHIAN, Brand Lead, US Immunology, UCB Pharma
• LOUISE ST-ONGE, Head of Pricing, Market Access & Government Affairs, Mitsubishi Tanabe Pharma (Canada)
• RYAN CLEMENTS, Managing Director, KPMG
• JOLIE APICELLA, Partner, Wiggin and Dana
• REED STEPHENS, Partner, Winston & Strawn
• TED KARNEZIS, Owner, Karnezis Consulting
• NEIL PALMER, Principal Consultant, WN Palmer
• RUJUL DESAI, Partner, Covington & Burling
• SARA SIMON, Attorney at Law, Porzio Bromberg & Newman

Plus more joining soon

KEY THEMES DISCUSSED IN THIS CONFERENCE

• Implications for companies – What to Prepare for 2025?
• Pharma pricing and market access in the US: From Dream to Reality
• The new normal: HTA & Reimbursement challenges in a post-pandemic world
• Prioritising Prioritizing patient-centred care
• The rise of digital health and value-based healthcare
• Implementing a pricing and market access strategy
• HTA and decision making in the reimbursement of medicines
• Payer’s perspective – What are they looking for?
• Importance of working together - Stakeholders- Industry, Payers, Physicians & Patients
• Evidence Generation - The strategic rigor and creativity applied to evidence generation
• Developing risk-sharing reimbursement models and value-based pricing
• The international pricing system
• Integrating real-world data into pricing
• Patient engagement and adherence within the environment
• Adding value through an innovative patient-centred approach
• Robust patient services & reimbursement support program for biosimilar products
• Recent regulatory updates & development

Enjoy and make the best out of our dedicated networking time, meet the leading international vendors showcasing the products of tomorrow in the co-located exhibition. Expand your knowledge of the latest business models and strategies in the high-level conference.